Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multicenter, Randomized, Double-blind, Parallel, Placebo-controlled Phase III Clinical Trial, to Evaluate the Efficacy and Safety of HRS-5965 Capsule in Primary IgA Nephropathy

NCT07014826 is registered in ClinicalTrials.gov with Chengdu Suncadia Medicine Co., Ltd. as lead sponsor.

NCT NCT07014826
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07014826 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multicenter, Randomized, Double-blind, Parallel, Placebo-controlled Phase III Clinical Trial, to Evaluate the Efficacy and Safety of HRS-5965 Capsule in Primary IgA Nephropathy
Lead sponsor
Chengdu Suncadia Medicine Co., Ltd.
Phase
Phase 3
Overall status
Recruiting
Start date
June 4, 2025
Completion date
December 31, 2028
Enrollment
378 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

primary iga nephropathy